



PRESS RELEASE

## Sosei Heptares' President & CEO and Head of UK R&D to Participate in a 'Fireside Chat' at the Jefferies London Healthcare Conference 2022

Tokyo, Japan and Cambridge, UK, 9 November 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO, Chris Cargill, and Matt Barnes, Head of UK R&D, will participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference on Tuesday, 15 November at 11:30 a.m. GMT / 6:30 a.m. ET / 8:30 p.m. JST.

The live webcast of the ‘Fireside Chat’ will be available [here](#).

The replay will also be available at the same link for 90 days post the event.

-ENDS-

### About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR<sup>®</sup> technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.

We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR<sup>®</sup> are trademarks of Sosei Group companies.

For more information, please visit [soseiheptares.com](https://soseiheptares.com)

LinkedIn: [@soseiheptaresco](#) | Twitter: [@soseiheptaresco](#) | YouTube: [@soseiheptaresco](#)

Enquiries:

### Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, Chief Financial Officer

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Candelle Chong, SVP Investor Relations and Corporate Strategy



PRESS RELEASE

*Japan:* +81 (0)3 5210 3399 | *United Kingdom:* +44 (0)1223 949390 | [IR@SoseiHeptares.com](mailto:IR@SoseiHeptares.com)

**MEDiSTRAVA Consulting (for International Media)**

Mark Swallow, Frazer Hall, Eleanor Perkin

+44 (0)203 928 6900 | [SoseiHeptares@medistrava.com](mailto:SoseiHeptares@medistrava.com)

**Forward-looking statements**

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.